NTRK1 and glioblastoma: To the best of our knowledge, this is the first report in glioblastoma that documents loss of receptor tyrosine kinase gene amplification in patient’s tumour after direct molecularly targeted inhibition with a small molecule agent, an observation reported in other cancers22,23.